A single change to even one of the thousands of DNA codes that make up each gene in the human genome can result in severe diseases such as cancer, cystic fibrosis, muscular dystrophy or Huntington's Disease. A similarly minor ...
Apr 7, 2011
0
0
Using a pair of powerful genome-search techniques, researchers from the Harvard School of Public Health (HSPH), Harvard University, and the Broad Institute have identified several genes that may be implicated in the malaria ...
Apr 21, 2011
0
0
In the largest study of its kind to date, researchers at Stanford University School of Medicine and their colleagues have found that worldwide only a limited number of mutations are responsible for most cases of transmission ...
Apr 7, 2015
0
119
Imatinib, better known as Gleevec, was hailed as a "miracle" cancer drug when it entered the market in the early 2000s. Though it has been highly successful at treating early-stage chronic myeloid leukemia (CML)—a rare ...
Jun 1, 2022
0
150
Scientists have spotted signs of 'pre-resistance' in bacteria for the first time—signs that particular bacteria are likely to become resistant to antibiotics in the future—in a new study led by UCL and Great Ormond Street ...
Dec 15, 2021
0
78
With drug-resistant bacteria on the rise, even common infections that were easily controlled for decades—such as pneumonia or urinary tract infections—are proving trickier to treat with standard antibiotics.
Jan 2, 2015
1
123
In order for cancer to form in the human body, normal cells must acquire multiple mutations before they develop toward the disease. It was previously believed that these mutations acted in concert in the progression of cancer. ...
Jul 22, 2020
0
43
(Medical Xpress) -- Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted ...
Jun 3, 2011
0
0
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit ...
Aug 2, 2011
0
0
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...
Oct 17, 2017
0
5
